Literature DB >> 3478136

Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells.

M L Dell'Aquila1, H T Nguyen, C L Herald, G R Pettit, P M Blumberg.   

Abstract

Phorbol esters inhibit chemically induced differentiation in Friend erythroleukemia cells. This study examines the effect of the macrocyclic lactone bryostatin 1 on phorbol ester responses in a Friend erythroleukemia cell clone, PS 7. In several biological systems, bryostatin 1 was reported to mimic phorbol ester action, including activation of protein kinase C, but in HL-60 cells it blocked phorbol ester-induced differentiation. We report here that bryostatin 1 blocks phorbol ester action in Friend cells (clone PS 7), a second differentiating system. In this system, in contrast to HL-60 cells, the phorbol esters inhibit rather than induce differentiation. Bryostatin 1 restores the differentiation response [50% effective dose, 15 +/- 3.5 nM (SEM)] as well as blocks a second phorbol ester effect, induction of cellular adherence. The inhibition of erythroid differentiation by dexamethasone, a nonphorbol compound whose action presumably is not protein kinase C mediated, is unaffected by bryostatin 1. Although bryostatin 1 inhibits [3H]phorbol 12,13-dibutyrate binding in intact Friend erythroleukemia cell clone PS 7, the mechanism for the antagonism of phorbol ester action by bryostatin 1 in Friend cells cannot be explained by simple competition at the binding site.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3478136

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.

Authors:  K G Steube; D Grunicke; H G Drexler
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

2.  Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.

Authors:  P A Wender; C M Cribbs; K F Koehler; N A Sharkey; C L Herald; Y Kamano; G R Pettit; P M Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

3.  The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.

Authors:  P A Wender; J DeBrabander; P G Harran; J M Jimenez; M F Koehler; B Lippa; C M Park; C Siedenbiedel; G R Pettit
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

4.  Distinct modulatory effects of bryostatin 1 and staurosporine on the biosynthesis and expression of the HIV receptor protein (CD4) by T cells.

Authors:  W M Boto; L Brown; J Chrest; W H Adler
Journal:  Cell Regul       Date:  1991-02

Review 5.  Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents.

Authors:  A Gescher
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

Review 6.  Review of survival analyses published in cancer journals.

Authors:  D G Altman; B L De Stavola; S B Love; K A Stepniewska
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

7.  A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

Authors:  G C Jayson; D Crowther; J Prendiville; A T McGown; C Scheid; P Stern; R Young; P Brenchley; J Chang; S Owens
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.